A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care

Inclusion Criteria: * Participants aged 18 years or older. * Investigator-confirmed documented diagnosis of CIDP of any type (e.g., typical, multifocal, focal, motor, sensory, or distal) according to the revised European Academy of Neurology and Peripheral Nerve Society (EAN/PNS) 2021 guidelines on the diagnosis and treatment of CIDP. * Participants must currently have a stable disease course (as per physician judgment) for at least 12 weeks. * Is considered a new user or current user of HyQvia- * New users (Cohort A) are participants on a CIDP treatment as of the date of enrollment, who intend to switch to HyQvia within 6 weeks after enrollment. * Current users (Cohort B) are participants on HyQvia as of the date of enrollment, who switched to HyQvia within the 6 weeks preceding the date of enrollment (the 6-week window may be extended depending on the recruitment progress). * Has provided written informed consent (for the main study). * Participant is willing to comply with the protocol requirement of non-standard of care (non-SOC) assessments (e.g., adjusted inflammatory neuropathy cause and treatment (INCAT) assessment). * Participants must be able to communicate fluently in their local language (if they participate in the optional qualitative participant interview \[sub-study\]. Exclusion Criteria: * Had any HyQvia use, defined as * any record of HyQvia use prior to enrollment for new users of HyQvia (Cohort A), and * any record of HyQvia use more than 6 weeks preceding the enrollment date (the 6-week window may be extended depending on the recruitment progress) for current users of HyQvia (Cohort B). * Without any prior treatment for CIDP. * Pregnant or breastfeeding. * Participants with known hypersensitivity to any component of HyQvia. * Has participated in an interventional clinical study within 30 days prior to enrollment or was scheduled to participate in an interventional clinical study during this study. * Has had major surgery within 12 weeks prior to enrollment, or has surgery planned during the time the participant is expected to participate in the study. Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgeries. * Received induction treatment for CIDP during the past 12 weeks. * Participant is identified by the investigator as being unable or unwilling to cooperate with the study procedures. * (Cohort A) only: Participants who do not initiate HyQvia treatment within 6 weeks after enrollment.